Please assess the completion status of the following clinical trial:

Trial Title: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NF2 by National Institutes of Health (NIH) criteria~* Age ≥ 16 years~* Progressive VS growth during the previous 12 months.~* WHO performance status \> or = 2~* Adequate bone marrow, liver and renal function.~* For women of childbearing potential, no pregnancy or breast-feeding~* Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.~* Willingness to provide informed consent~Exclusion Criteria:~* Inability to tolerate periodic MRI scans or gadolinium contrast.~* Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing.~* Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed.~* Radiation therapy for the target lesion in the 60 months preceding inclusion in the study.~* Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug.~* Immunization with attenuated live vaccines within one week of study entry or during study period.~* Presence of a fungal infection requiring systemic antifungal treatment at enrollment~* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.~* Patients who have any severe and/or uncontrolled medical conditions.~* Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients.~* Patients unwilling to or unable to comply with the protocol

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RAD001 Treatment (Type: EXPERIMENTAL): All subjects will be given RAD001 for 1 year (12 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).